Wells Fargo raises Ascendis Pharma stock price target on growth outlook
Wells Fargo raised its price target for Ascendis Pharma (ASND) to $330 from $326, citing strong growth prospects and underappreciated operating leverage. The company reported Q3 earnings and revenue exceeding estimates, driven by its rare-disease portfolio. Management expects continued growth in Yorvipath, with international expansion supporting a €5 billion 2030 revenue target.
How this was made
The 30-second read
Why it matters
The earnings beat and higher target may attract new buying, especially from investors focused on high‑margin biotech firms.
Market read
Positive earnings and analyst upgrade provide a short‑term catalyst for ASND.
What to watch
Potential regulatory or reimbursement risks for rare‑disease therapies.
Background
Ascendis Pharma reported Q3 earnings that beat expectations and raised its revenue outlook, prompting Wells Fargo to lift its price target.
Ticker impact
Wells Fargo raised its price target on Ascendis Pharma to $330 and reported better‑than‑expected Q3 earnings and revenue.
potential upside as the market prices in higher earnings expectations
The price‑target increase and earnings beat are fresh facts that can drive buying interest.
Market effects
Strong earnings may lift other rare‑disease biotech peers.
U.S. biotech sector could see modest gains.
Limited to biotech investors; no broad market effect.
Counterpoint
If the growth outlook proves overly optimistic, the stock could face a pull‑back.
Key entities
- companyAscendis Pharma
Biopharma focused on rare‑disease treatments.
- analystWells Fargo
Raised price target to $330.

